References
- Alabaster C.T., Bell A.S., Campbell S.F., Ellis P., Hnederson C.G., Morris D.S., Roberts D.A., Ruddock K.S., Samuels G. M. R., Stefaniak M.H. 2 (1H)-Quinolones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five membered heteroaryl) derivatives. Journal of Medicinal Chemistry 1989; 32: 575–583
- Bastain W., Boyce M.J., Stafford L.E., Morton P.B., Clark D.A., Marlow H.F. Pharmacokinetics of Xamoterol after intravenous and oral administration to volunteers. European Journal of Clinical Pharmacology 1988; 34: 469–473
- Clark B., Smith D.A. Drug metabolism studies in safety evaluation. Progress on Drug Metabolism, Vol. 11, G.G. Gibson. Taylor & Francis, London 1988; 175–216
- Dalrymple H.W., Burges R.A., Blackburn K.J., Arrowsmith J.E., Cross P.E., Higgins A.J. UK-68, 798 is a novel, potent and selective Class III antiarrhythmic drug. Journal of Molecular Cell Cardiology 1989; 21(suppl. II)S11
- Grant S.M., Clissold S.P. Fluconazole, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877–916
- Green S.V., Krebbs H.A., Lemieux R.E., Cheng L.K. Determination of a new anti-allergenic agent, 1-[4-[3-[4-[bis-(4-fluorophenyl)hydroxymethyl]-1-piperdinyl]propoxy]-3- methoxylphenyl]-ethanone and its active acidic metabolite in plasma by high performance liquid a chromatography. Journal of Chromatography 1990; 527: 397–405
- Hansch C., Bjorkroth J.P., Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. Journal of Pharmaceutical Sciences 1987; 76: 663–687
- Jardine A.G., Connell J. M. C., Cussans N.J., Dilly S.G., Leckie B.J., Northridge D.B. Pharmacological evaluation of endogenous atrial natriuretic factor in man using the atriopeptidase inhibitor UK-69,578. Journal of the American College of Cardiology 1989; 13(Suppl. A)76A
- Heykants J., van Peer A., van de Velde V., van Rooy P., Meuldermans W., Lavrijsen K., Woestenborghs R., van Cutsem J., Cauwenbergh G. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32(Suppl. 1)67–87
- Humphrey M.J., Jevons S., Tarbit M.H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole and antifungal drug, in animals and man. Antimicrobial Agents and Chemotherapy 1985; 28: 648–653
- Marten T.R., Bourne G.R., Miles G.S., Shuker B., Rankine H.D., Dutka V.N. The metabolism of ICI 118,587, a partial agonist of β1-adrenoceptors, in mice, rats, rabbits, dogs and humans. Drug Metabolism and Disposition 1984; 12: 652–660
- Northridge D.B., Alabaster C.T., Barclay P.L., Connell J. M. C., Dargie H.J., Dilly S.G., Findlay I.N., Jardine A.G., Lever A.F., Samuels G. M. R. Effects of UK-69,578: a ncvei atriopeptidase inhibitor. Lancet 1989; ii: 591–593
- Paton D.M., Webster D.R. Clinical pharmacokinetics of H1-receptor antagonists. Clinical Pharmacokinetics 1985; 10: 477–497
- Riegger G. A. J., Kahles H.W., Ferstl B.P., Kromer E.P., Kochsiek K. Acute effects of atriopeptidase inhibitor UK-79,300 in patients with chronic congestive heart failure. Circulation 1989; 80(Pt 4 Suppl. II)110–111
- Smith D.A., Humphrey M.J., Charuel C. Design of toxicokinetic studies. Xenobiotica 1990; 20: 1187–1199
- Swanson B.N., Stauber K.L., Alpaugh W.C., Wenstein S.H. Radioenzymatic assay of on angiotensin-converting enzyme inhibitors in plasma and urine. Analytical Biochemistry 1985; 148: 401–407
- Walker D.K., Aherene G.W., Arrowsmith J.E., Cross P.E., Kaye B., Smith D.A., Stopher D.A., Wild W. Measurement of the Class III antidysrhythmic drug, UK-68,798 in plasma by radioimmunoassay. Journal of Pharmaceutical and Biomedical Analysis 1991; 9: 141–149